#BitMart is thrilled to announce the primary listing of Stage Point Europe Token (SPET) @StagePointEU🎉💰Trading pair: SPET/USDT💎Deposit: 07/21/2025 2:00 PM UTC💎Trading: 07/22/2025 2:00 PM UTC🔥Register Now: https://t.co/AVKytAseHb🔗Learn more: https://t.co/qRVfhKvkuM https://t.co/2oxEylspCD ...

🗞️ #BitMart Crypto Daily — 17 Jul 20251️⃣ Bitcoin trades at $118,634, up 0.65% in the last 24 hours.2️⃣ Ethereum surges past $3,400 to $3,439 after a 20% weekly gain.3️⃣ Trump memecoins unlock 45% additional supply ahead of “Crypto Week” votes.4️⃣ MultiBank’s MBG token bridges Web3 and traditional finance with real-world asset backing.5️⃣ #BitMart launches a $SPET #PowerDrop event—30,000 USDT total supply for Stage Point Europe Token.Am I missing anything? Tell me more 👇 ...

🚀 Exciting News! Stage Point Europe Token(SPET) @StagePointEU is set to list on BitMart Powerdrop! 🌐🌐 Total Supply: 30,000 USDT in SPET⏳ 3-STEPS TO SLAY: KYC1 → EARN TICKETS → SPLIT THE POT🔒 Requirement: Complete KYC1 by July 20, 2:00 AM UTC🚀 Period: 7/17/2025 2:00 AM UTC – 7/23/2025 4:00 AM UTC📌 Details: https://t.co/1xyOVwG0A5🔥 Join now: https://t.co/7aCgSvoJKG#SPET #BitMartPowerdrop #CryptoNews ...

SAN DIEGO and TORONTO, July 15, 2025 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. ("Aptose" or the "Company") (TSX: APS; OTC: APTOF), a clinical-stage precision oncology company developing a tuspetinib (TUS) based triple drug frontline therapy to treat patients with newly diagnosed acute myeloid leukemia (AML), today announced that it has received an additional advance of US$2.0M from Hanmi Pharmaceutical Co. Ltd. (“Hanmi”), as part of a US$8.5M loan facility agreement with Hanmi (the “Loan Agreement”) annou ...

Group 1 - Aptose Biosciences Inc. has been upgraded to trade on the OTCQB Market under the ticker symbol "APTOF" starting July 1, 2025, while continuing its listing on the Toronto Stock Exchange (TSX) under "APS" [1] - The OTCQB Venture Market is designed for early-stage and developing companies that are current in their reporting and undergo an annual verification process [2] - Aptose is a clinical-stage biotechnology company focused on developing precision medicines for oncology, particularly in hematology, with its lead product being the oral kinase inhibitor tuspetinib (TUS) [3]

Core Insights - Aptose Biosciences Inc. has entered into an Interest Deferral Agreement with Hanmi Pharmaceutical Co., Ltd. to defer interest payments on a loan facility agreement [1] - The deferral period for the interest payments extends from December 21, 2024, to March 31, 2025, and from June 27, 2025, to December 31, 2025 [1] Company Overview - Aptose Biosciences is a clinical-stage biotechnology company focused on developing precision medicines for oncology, particularly in hematology [2] - The company's lead compound, tuspetinib (TUS), is an oral kinase inhibitor showing efficacy as both a monotherapy and in combination therapy for relapsed or refractory acute myeloid leukemia (AML) [2] - Tuspetinib is being developed as a frontline triplet therapy for newly diagnosed AML patients [2]

SAN DIEGO and TORONTO, June 20, 2025 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. ("Aptose" or the "Company") (TSX: APS; OTC: APTOF), a clinical-stage precision oncology company developing a tuspetinib (TUS) based triple drug frontline therapy to treat patients with newly diagnosed acute myeloid leukemia (AML), today announced that it has entered into a new loan agreement (the “Loan Agreement”) with Hanmi Pharmaceutical Co. Ltd. (“Hanmi”). The Loan Agreement is an uncommitted facility for up to US$8.5million ...

Core Insights - Aptose Biosciences Inc. presented data from its Phase 1/2 TUSCANY trial for newly diagnosed AML patients treated with tuspetinib in combination with venetoclax and azacitidine at the EHA 2025 Congress [1][3] Group 1: Study Overview - The TUS+VEN+AZA triplet is being developed as a mutation-agnostic frontline therapy for newly diagnosed AML patients who cannot receive induction chemotherapy [2][8] - The TUSCANY trial is designed to test various doses of tuspetinib in combination with standard dosing of azacitidine and venetoclax [9] Group 2: Key Findings - The addition of tuspetinib to standard care creates a well-tolerated and mutation-agnostic frontline therapy for newly diagnosed AML [5] - Ten AML patients have been treated with the TUS+VEN+AZA combination, with complete remissions and minimal residual disease negativity observed across diverse mutations [6][7] - At the 40 mg dose level, three out of four patients achieved complete remissions and were MRD-negative, while at the 80 mg dose level, all three patients achieved composite complete remissions [6] Group 3: Safety and Efficacy - No dose-limiting toxicities (DLTs) have been observed to date, and all ten subjects treated remain alive [6][7] - TUS demonstrated activity across diverse genetic populations, including those with adverse TP53 mutations [6][8] - The triplet therapy continues to be well tolerated, with no treatment-related deaths or significant adverse events reported [6][7]

TUS+VEN+AZA triplet achieves complete remissions (CRs) and minimal residual disease (MRD)-negativity with favorable safety in newly diagnosed AML patientsCompleted 40 mg and 80 mg TUS dose cohorts; no prolonged myelosuppression or dose-limiting toxicitiesNo dose reductions required to the standard-of-care therapy with 40 mg and 80 mg TUS dose cohortsCSRC endorsed escalation to 120 mg TUS dosingFirst patient dosed with 120 mg TUS triplet and enrollment continues SAN DIEGO and TORONTO, May 20, 2025 (GLOBE NE ...

Highlights Progress in TUSCANY Clinical Trial of Tuspetinib in AML Triple Frontline TherapySAN DIEGO and TORONTO, May 08, 2025 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (TSX: APS and OTC: APTOF), a clinical-stage precision oncology company developing a tuspetinib (TUS)-based triple drug frontline therapy to treat patients with newly diagnosed acute myeloid leukemia (AML), today announced financial results for the first quarter ended March 31, 2025, and provided a corporate upda ...